Compare USLM & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | EVO |
|---|---|---|
| Founded | 1948 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | USLM | EVO |
|---|---|---|
| Price | $127.62 | $3.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 83.3K | ★ 255.2K |
| Earning Date | 02-02-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 32.23 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | $364,849,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $22.64 | N/A |
| Revenue Next Year | $8.38 | $8.52 |
| P/E Ratio | $27.99 | ★ N/A |
| Revenue Growth | ★ 20.27 | N/A |
| 52 Week Low | $80.47 | $2.84 |
| 52 Week High | $137.96 | $4.80 |
| Indicator | USLM | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 71.15 |
| Support Level | $118.57 | $3.10 |
| Resistance Level | $129.09 | $3.23 |
| Average True Range (ATR) | 4.10 | 0.08 |
| MACD | -0.15 | 0.07 |
| Stochastic Oscillator | 69.71 | 98.73 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.